
Opinion|Videos|July 8, 2024
Emerging Pathways and Role of TROP2-Directed ADCs in HR+/HER2- mBC
Author(s)Aditya Bardia, MD, MPH, Laura Huppert, MD
Medical oncologists provide insights on emerging pathways and TROP2-directed antibody-drug conjugates in HR+/HER2- metastatic breast cancer, highlighting ongoing research.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- Please comment on emerging pathways and how they might impact the future treatment landscape for patients with HR+/HER2-negative metastatic breast cancer.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5



































